Why the study?
Patients with T2DM face poor cardiovascular outcomes after STEMI, and it is unknown whether visit-to-visit fasting plasma glucose variability predicts left ventricular adverse remodeling in this population.
Does high visit-to-visit fasting plasma glucose variability predict left ventricular adverse remodeling in T2DM patients with STEMI?
Does high visit-to-visit fasting plasma glucose variability predict left ventricular adverse remodeling in T2DM patients with STEMI?
High visit-to-visit fasting plasma glucose variability is an independent predictor of left ventricular adverse remodeling in patients with type 2 diabetes following STEMI.
Answers are grounded in this paper and cite their sources.
Should not yet change post-STEMI care in T2DM; supports prospective trials on FPG variability and LVAR.
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) are predisposed to poor cardiovascular outcomes after ST-segment elevation myocardial infarction (STEMI). Left ventricular adverse remodeling (LVAR) triggered upon myocardial infarction is recognized as the predominant pathological process in the development of heart failure. In the present study, we sought to investigate whether visit-to-visit fasting plasma glucose (FPG) variability is a potential predictor of LVAR in T2DM patients after STEMI. METHODS: From January 2014 to December 2018 in Ruijin Hospital, T2DM patients with STEMI who underwent primary percutaneous coronary intervention were consecutively enrolled and followed up for ~ 12 months. The changes in left ventricular geometric and functional parameters between baseline and 12-month follow-up were assessed by echocardiography. The incidence of LVAR, defined as 20% increase in indexed left ventricular end-diastolic volume (LVEDV), and its relationship with visit-to-visit FPG variability were analyzed. Multivariate regression models were constructed to test the predictive value of FPG variability for post-infarction LVAR. In multivariate analysis, FPG variability was independently associated with incidence of post-infarction LVAR after adjustment for traditional risk factors, baseline HbA1c as well as mean FPG during follow-up (OR: 3.021 [95% CI 1.081-8.764] for highest vs. lowest tertile of CV of FPG). Assessing FPG variability by other two measures, including standard deviation (SD) and variability independent of the mean (VIM), yielded similar findings. CONCLUSIONS: This study suggests that visit-to-visit FPG variability is an independent predictor of incidence of LVAR in T2DM patients with STEMI. Trial registration Trials number, NCT02089360; registered on March 17,2014.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: